Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. Newsroom/
    3. Immunology /
    4. New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Haemolytic Disease of the Foetus and Newborn (HDFN)
    Immunology

    New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Haemolytic Disease of the Foetus and Newborn (HDFN)

    New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Haemolytic Disease of the Foetus and Newborn (HDFN)